A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.

Abstract

Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease. Both contain the same human enzyme, alpha-galactosidase A, but they are… (More)

Topics

11 Figures and Tables

Cite this paper

@article{Lee2003ABA, title={A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.}, author={Karen L. Lee and Xiaoying Jin and Kate Zhang and Lorraine Copertino and Laura Andrews and Jennifer Baker-Malcolm and Laura B Geagan and Huawei Qiu and Keirsten Seiger and Debra Barngrover and John M. McPherson and Tim Edmunds}, journal={Glycobiology}, year={2003}, volume={13 4}, pages={305-13} }